PHILLIP MARLOWE: Open Payments
NPI 1760044424 · IDAHO FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,059 in 112 payments from 27 companies in 2025. Trend: 2023 $2,549 · 2024 $1,944 · 2025 $2,059
Food & beverage: $2,059
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $404 |
| Otsuka America Pharmaceutical, Inc. | 11 | $155 |
| Vanda Pharmaceuticals Inc. | 8 | $148 |
| Aimmune Therapeutics, Inc. | 5 | $114 |
| Lilly USA, LLC | 6 | $105 |
| Axsome Therapeutics, Inc. | 6 | $101 |
| GENZYME CORPORATION | 5 | $96 |
| Grifols USA, LLC | 4 | $95 |
| Astellas Pharma US Inc | 3 | $81 |
| Amgen Inc. | 5 | $78 |
Products named: REXULTI, QULIPTA, VRAYLAR, FANAPT, MOUNJARO, DUPIXENT, Prolastin-C Liquid, ZENPEP.
Industry payments across ID — which companies pay providers there.
